{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:42Z","timestamp":1792718322589,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jaad.2016.12.005","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T08:30:39Z","timestamp":1485592239000},"page":"736-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":484,"title":["JAK inhibitors in dermatology: The promise of a new drug class"],"prefix":"10.1016","volume":"76","author":[{"given":"William","family":"Damsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, Jaks, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The jaK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"6544","key":"10.1016\/j.jaad.2016.12.005_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in\u00a0patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"issue":"5237","key":"10.1016\/j.jaad.2016.12.005_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-016-0410-8","article-title":"Genetics of Cutaneous T cell lymphoma: from bench to bedside","volume":"17","author":"Damsky","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jaad.2016.12.005_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr Opin Chem Biol"},{"issue":"9","key":"10.1016\/j.jaad.2016.12.005_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of\u00a0cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.jaad.2016.12.005_bib8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2016.12.005_bib9","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J\u00a0Med Chem"},{"issue":"13","key":"10.1016\/j.jaad.2016.12.005_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib11","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5646","key":"10.1016\/j.jaad.2016.12.005_bib12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/vde.12088","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.jaad.2016.12.005_bib15","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety\u00a0and\u00a0efficacy of the JAK inhibitor tofacitinib citrate in\u00a0patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2016.12.005_bib17","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib\u00a0induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2016.12.005_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2016.12.005_bib20","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral\u00a0tofacitinib reverses alopecia universalis in a patient with\u00a0plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","article-title":"Tofacitinib Citrate for the treatment of nail dystrophy associated with alopecia universalis","volume":"152","author":"Dhayalan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000445182","article-title":"Transient efficacy of tofacitinib in alopecia areata universalis","volume":"8","author":"Anzengruber","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib24","doi-asserted-by":"crossref","unstructured":"U. Mrowietz, S. Gerdes, R. Glaser, O. Schroder, Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. http.\/\/dx.doi.org\/10.2340\/00015555-2491, published online June 28, 2016.","DOI":"10.2340\/00015555-2491"},{"issue":"8","key":"10.1016\/j.jaad.2016.12.005_bib25","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2016.12.005_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jaad.2016.12.005_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jaad.2016.12.005_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jaad.2016.12.005_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2016.09.008","article-title":"Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis","volume":"3","author":"Vesely","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation","volume":"62","author":"Mossner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2016.12.005_bib35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for\u00a0refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib36","doi-asserted-by":"crossref","unstructured":"J.J. Paik, L. Christopher-Stine, A case of refractory dermatomyositis responsive to tofacitinib, Semin Arthritis Rheum. http:\/\/dx.doi.org\/10.2340\/00015555-2491, published online August 17, 2016.","DOI":"10.2340\/00015555-2491"},{"issue":"26","key":"10.1016\/j.jaad.2016.12.005_bib37","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jdcr.2016.10.009","article-title":"Idiopathic erythema multiforme: evidence of underlying JAK-STAT activation and successful treatment with tofacitinib","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jaad.2016.12.005_bib39","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2016.12.005_bib40","doi-asserted-by":"crossref","unstructured":"King B, Lee AI, Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol. doi: 10.1016\/j.jid.2016.10.044. Published online November 22, 2016.","DOI":"10.1016\/j.jid.2016.10.044"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2015.1069473","article-title":"Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis","volume":"26","author":"Yamamoto","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib42","doi-asserted-by":"crossref","unstructured":"N. Konig, C. Fiehn, C. Wolf, et\u00a0al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2016-209841, published online August 26, 2016.","DOI":"10.1136\/annrheumdis-2016-209841"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib43","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","article-title":"Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis","volume":"4","author":"Yacoub","year":"2016","journal-title":"Biomark Res"},{"key":"10.1016\/j.jaad.2016.12.005_bib45","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"136","author":"Fremond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.005_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clim.2016.10.003","article-title":"Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation","volume":"173","author":"Koga","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.005_bib47","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib48","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2016.12.005_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy\u00a0and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key\u00a0inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2016.12.005_bib53","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib54","unstructured":"ClinicalTrials.gov. NCT02809976. 2016."},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib55","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and\u00a0adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2016.12.005_bib56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2016.12.005_bib58","first-page":"e24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"issue":"3","key":"10.1016\/j.jaad.2016.12.005_bib59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase\u00a0inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib60","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2016.03.008","article-title":"Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies","volume":"15","author":"Gilhar","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2016.12.005_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S82599","article-title":"Profile of tofacitinib citrate and its\u00a0potential in the treatment of moderate-to-severe chronic\u00a0plaque psoriasis","volume":"10","author":"Di Lernia","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib63","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"223","key":"10.1016\/j.jaad.2016.12.005_bib64","doi-asserted-by":"crossref","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a\u00a0mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib66","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"10.1016\/j.jaad.2016.12.005_bib67","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib68","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib70","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Arana Yi","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jaad.2016.12.005_bib71","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2016.1185414","article-title":"Safety considerations when treating myelofibrosis","volume":"15","author":"O'Sullivan","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.jaad.2016.12.005_bib72","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of\u00a0tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jaad.2016.12.005_bib75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib76","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.005_bib77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib78","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/14740338.2014.916273","article-title":"Safety evaluation of ruxolitinib for treating myelofibrosis","volume":"13","author":"Galli","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib79","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/ajt.13181","article-title":"Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients","volume":"15","author":"Vincenti","year":"2015","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.jaad.2016.12.005_bib80","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2009.02720.x","article-title":"Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients","volume":"9","author":"Busque","year":"2009","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.jaad.2016.12.005_bib81","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib82","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.12.005_bib83","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2016.12.005_bib84","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"issue":"3-4","key":"10.1016\/j.jaad.2016.12.005_bib86","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000347184","article-title":"Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis","volume":"91","author":"Fujii","year":"2013","journal-title":"Pharmacology"},{"issue":"9","key":"10.1016\/j.jaad.2016.12.005_bib87","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation\u00a0of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"The Journal of investigative dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2016.12.005_bib88","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2015.03.001","article-title":"Clinical perspectives and murine models of lichenoid tissue reaction\/interface dermatitis","volume":"78","author":"Okiyama","year":"2015","journal-title":"Journal of dermatological science"},{"key":"10.1016\/j.jaad.2016.12.005_bib89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mehy.2016.04.042","article-title":"Targeting the IFN-gamma\/CXCL10 pathway in lichen planus","volume":"92","author":"Di Lernia","year":"2016","journal-title":"Med Hypotheses"},{"issue":"10","key":"10.1016\/j.jaad.2016.12.005_bib90","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jaad.2016.12.005_bib91","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1136\/annrheumdis-2014-205615","article-title":"Tofacitinib, a JAK inhibitor, inhibits human B\u00a0cell\u00a0activation in\u00a0vitro","volume":"73","author":"Wang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1-3","key":"10.1016\/j.jaad.2016.12.005_bib92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","article-title":"The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia","volume":"582","author":"Kudlacz","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib93","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib94","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of\u00a0selective JAK1 inhibitor GSK2586184 for the treatment of\u00a0psoriasis in a randomized placebo-controlled phase IIa\u00a0study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"The British journal of dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2016.12.005_bib95","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral Janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"18","key":"10.1016\/j.jaad.2016.12.005_bib96","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","article-title":"Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases","volume":"58","author":"Farmer","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaad.2016.12.005_bib97","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cpdd.273","article-title":"Pharmacokinetics, pharmacodynamics, and safety of ASP015K (peficitinib), a\u00a0new Janus kinase inhibitor, in healthy subjects","volume":"5","author":"Cao","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.jaad.2016.12.005_bib98","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jaad.2016.12.005_bib99","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2016.12.005_bib100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216311884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216311884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:19Z","timestamp":1759272139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216311884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0190962216311884"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727254538.793528317","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors in dermatology: The promise of a new drug class","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}